Department of Experimental Cardiology, Masonic Medical Research Institute, Utica, NY 13501 USA.
Nanion Technologies, 1 Naylon Ave. Suite C, Livingston, NJ 07039, USA.
Biochem Pharmacol. 2019 Nov;169:113608. doi: 10.1016/j.bcp.2019.08.010. Epub 2019 Aug 26.
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are used for many applications including safety pharmacology. However, a deficiency or complete absence of several K currents suggests repolarization reserve is low in hiPSC-CMs. We determined whether a dual I and I activator can improve repolarization reserve in hiPSC-CMs resulting in a more electrophysiologically mature phenotype.
Human iPSC were maintained on growth factor and differentiated into the cardiac phenotype by addition of selective Wnt molecules. Current and voltage clamp recordings in single cells were made using patch electrodes. Extracellular field potentials were made using a microelectrode array on hiPSC monolayers. Action potential recordings from hiPSC-CMs following application of an I inhibitor resulted in depolarization of the membrane potential and prolongation of the APD. A flattening of the T-wave was noted on the pseudo-ECG. In contrast, application of the I and I agonist, NS3623, resulted in hyperpolarization of the membrane, slowing of the spontaneous rate and shortening of the APD. Voltage clamp recording showed a significant increase in I; no enhancement of I in hiPSC-CMs was noted. AP clamp experiments revealed that I plays a role in both phase 3 repolarization and phase 4 depolarization. mRNA analysis revealed that KCNH2 is abundantly expressed in hiPSC-CM, consistent with electrophysiological recordings.
Although NS3623 is a dual I and I activator in ventricular myocytes, application of this compound to hiPSC-CMs enhanced only I and no effect on I was noted. Our results suggest I enhancement can improve repolarization reserve in this cell type. The disconnect between a dramatic increase in I in adult myocytes versus the lack of effect in hiPSC-CMs suggest that the translation of pharmacological effects in hiPSC-CM to adult myocytes should be viewed with caution.
人类诱导多能干细胞衍生的心肌细胞(hiPSC-CMs)被广泛应用于多种领域,包括安全药理学。然而,一些钾电流的缺乏或完全缺失表明 hiPSC-CMs 的复极储备较低。本研究旨在确定是否可以使用 I 和 I 双重激活剂来改善 hiPSC-CMs 的复极储备,使其表现出更成熟的电生理特性。
hiPSC 通过添加选择性 Wnt 分子在生长因子上维持,并分化为心脏表型。使用膜片钳电极在单个细胞中进行电流和电压钳记录。使用微电极阵列在 hiPSC 单层上进行细胞外场电位记录。在 hiPSC-CMs 中应用 I 抑制剂后,动作电位记录导致膜电位去极化和 APD 延长。在伪 ECG 上观察到 T 波变平。相反,应用 I 和 I 激动剂 NS3623 导致膜超极化、自发率减慢和 APD 缩短。电压钳记录显示 I 显著增加;但在 hiPSC-CMs 中未观察到 I 的增强。AP 钳位实验表明,I 在 3 相复极和 4 相去极化中均发挥作用。mRNA 分析显示 KCNH2 在 hiPSC-CM 中大量表达,与电生理记录一致。
尽管 NS3623 是心室肌细胞中的 I 和 I 双重激活剂,但该化合物在 hiPSC-CMs 中的应用仅增强了 I,而对 I 没有影响。我们的结果表明,I 的增强可以改善该细胞类型的复极储备。成人心肌细胞中 I 的显著增加与 hiPSC-CMs 中缺乏影响之间的脱节表明,应谨慎看待 hiPSC-CM 中药物效应向成人心肌细胞的转化。